Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Journal of Gastric Cancer|May 2, 2023
Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW StudyTakatsugu Ogata, Yukiya Narita, Zev A Wainberg, et al.
Bioengineering (Basel, Switzerland)|January 24, 2025
Neoplasms in the Nasal Cavity Identified and Tracked with an Artificial Intelligence-Assisted Nasal Endoscopic Diagnostic SystemXiayue Xu, Boxiang Yun, Yumin Zhao, et al.
Communications Biology|February 10, 2025
Multiple strategies association revealed functional candidate FASN gene for fatty acid composition in cattleBo Zhu, Tianzhen Wang, Qunhao Niu, et al.
BMC Cancer|July 28, 2023
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancerErnest Nadal, Mansoor Saleh, Santiago Ponce Aix, et al.
Journal for Immunotherapy of Cancer|March 10, 2021
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancerDavide Melisi, Do-Youn Oh, Antoine Hollebecque, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2020
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib TrialAmita Patnaik, Timothy A Yap, Hyun Cheol Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2019
Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic SyndromesValeria Santini, David Valcárcel, Uwe Platzbecker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsAntoine Hollebecque, Hyun C Chung, Maria J de Miguel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced CancerTimothy A Yap, Maria Vieito, Capucine Baldini, et al.
Bulletin of the World Health Organization|November 28, 2006
Community surveys and risk factor analysis of human alveolar and cystic echinococcosis in Ningxia Hui Autonomous Region, ChinaYu Rong Yang, Tao Sun, Zhengzhi Li, et al.
Pageof 9